Scientific Finding: EGFR is target for Chemotherapy

December 05, 2020

Los Angeles, CA (USC-Keck School of MedicineOriginal Article) April 5th, 2009

Abstract: The epidermal growth factor receptor (EGFR) is overexpressed in as many as 77% of colorectal cancer (CRC) cases. The EGFR is known to be involved in carcinogenetic processes such as cell proliferation, apoptosis, angiogenesis, cell motility, and metastasis. Preclinical and clinical studies have shown that targeting EGFR is a valid strategy for anticancer therapy. Currently, 2 classes of anti-EGFR agents are in phase II/III clinical development: monoclonal antibodies and tyrosine kinase (TK) inhibitors. The most established monoclonal antibody is cetuximab, the only EGFR inhibitor that is currently approved for use in patients with metastatic CRC. Several clinical studies of cetuximab, as a single agent or in combination with irinotecan, have shown promising efficacy in patients with metastatic CRC. READ MORE

published April 5th, 2005

Also in News

Guest Post: The Kindness Campaign discusses Skincare during Immunotherapy

January 04, 2022

Read More

Why does Lindi Skin contain fragrances?

December 01, 2021

Fragrance is one of the key decisions to be made when creating any skincare products, and our team of doctors, formulators and skincare experts created our formulas with very explicit instructions to design the products without any unnecessary fragrances, dyes, or ingredients.   

However, the key word here is “unnecessary”. 

Read More

"Be the solution" for a loved-one's skincare issues

November 16, 2021

Lindi Skin CEO Lindy Snider talks about how she created Lindi Skin because her friends could not find skincare to help with their skin issues from cancer treatments... and how you can help your loved ones by introducing them to Lindi Skin.

Read More

Liquid error: Could not find asset snippets/afterpay.liquid